

In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claims 3-7, 9, 15, 17, 20, 30-31, 34-35, and 39 without prejudice or disclaimer.

Please amend pending claims 1, 14, and 38 as noted below.

1. (Currently amended) An isolated TgAMA-1 polypeptide molecule ~~comprising~~ consisting essentially of an antigenic fragment of the polypeptide sequence set forth as amino acids 23-456 of SEQ ID NO:1.
2. (Original) A fusion protein comprising the antigenic polypeptide of claim 1.
- 3-13. (Cancelled)
14. (Currently Amended) A ~~vaccine~~ composition comprising the isolated TgAMA-1 polypeptide of claim 1 and an adjuvant.
- 15-22. (Cancelled)
23. (Original) A TgAMA-1 binding polypeptide that selectively binds to the isolated TgAMA-1 polypeptide of claim 1.
24. (Original) The TgAMA-1 binding polypeptide of claim 23, wherein the binding polypeptide is an antibody or antigen-binding fragment of an antibody.

25. (Original) The TgAMA-1 binding polypeptide of claim 24, wherein the antibody or antigen-binding fragment specifically binds to a region comprising about 12 or more cysteine residues of the isolated polypeptide of claim 1.

26. (Original) The TgAMA-1 binding polypeptide of claim 23, wherein the binding polypeptide blocks entry of Toxoplasma parasite into a cell.

27-37. (Cancelled)

38. (Previously Presented) The ~~vaccine~~-composition of claim 14, wherein the ~~vaccine~~ composition is a proteosome ~~vaccine~~.

39. (Cancelled)